KR100855457B1 - 악틴, 악티게닌 또는 그의 혼합물을 유효성분으로 함유하는피부미백용 화장료 조성물 - Google Patents
악틴, 악티게닌 또는 그의 혼합물을 유효성분으로 함유하는피부미백용 화장료 조성물 Download PDFInfo
- Publication number
- KR100855457B1 KR100855457B1 KR1020070020603A KR20070020603A KR100855457B1 KR 100855457 B1 KR100855457 B1 KR 100855457B1 KR 1020070020603 A KR1020070020603 A KR 1020070020603A KR 20070020603 A KR20070020603 A KR 20070020603A KR 100855457 B1 KR100855457 B1 KR 100855457B1
- Authority
- KR
- South Korea
- Prior art keywords
- actin
- skin
- arctigenin
- actinigen
- mixture
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 114
- 230000002087 whitening effect Effects 0.000 title claims abstract description 32
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 title claims abstract description 9
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 title claims abstract description 8
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 title claims abstract description 8
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 title claims abstract description 8
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 title claims abstract description 8
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 title claims abstract description 6
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 title claims abstract description 6
- 239000004480 active ingredient Substances 0.000 title claims description 10
- 150000001875 compounds Chemical class 0.000 title description 8
- 239000002537 cosmetic Substances 0.000 claims abstract description 54
- 239000006071 cream Substances 0.000 claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 10
- 239000006210 lotion Substances 0.000 claims abstract description 9
- 239000000344 soap Substances 0.000 claims abstract description 9
- 239000000839 emulsion Substances 0.000 claims abstract description 7
- 239000000499 gel Substances 0.000 claims abstract description 6
- 239000007921 spray Substances 0.000 claims abstract description 6
- 239000004094 surface-active agent Substances 0.000 claims abstract description 6
- 239000006072 paste Substances 0.000 claims abstract description 4
- 239000000725 suspension Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims abstract description 3
- 102000007469 Actins Human genes 0.000 claims description 66
- 108010085238 Actins Proteins 0.000 claims description 66
- 238000009472 formulation Methods 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 46
- 206010040880 Skin irritation Diseases 0.000 abstract description 10
- 231100000475 skin irritation Toxicity 0.000 abstract description 10
- 230000036556 skin irritation Effects 0.000 abstract description 10
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 abstract description 10
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 abstract description 9
- 101710200814 Melanotropin alpha Proteins 0.000 abstract description 9
- 240000005528 Arctium lappa Species 0.000 abstract description 5
- 235000003130 Arctium lappa Nutrition 0.000 abstract description 5
- 244000020518 Carthamus tinctorius Species 0.000 abstract description 5
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract description 5
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 abstract description 4
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 230000037353 metabolic pathway Effects 0.000 abstract description 4
- 229930182470 glycoside Natural products 0.000 abstract description 3
- 150000002338 glycosides Chemical class 0.000 abstract description 3
- 241000555712 Forsythia Species 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 40
- 230000000052 comparative effect Effects 0.000 description 24
- -1 Sangbaekpi Natural products 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 230000008099 melanin synthesis Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 11
- 102000003425 Tyrosinase Human genes 0.000 description 11
- 108060008724 Tyrosinase Proteins 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 230000002421 anti-septic effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000002752 melanocyte Anatomy 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 229920002554 vinyl polymer Polymers 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 229940113124 polysorbate 60 Drugs 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000576429 Forsythia suspensa Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 102000010825 Actinin Human genes 0.000 description 2
- 108010063503 Actinin Proteins 0.000 description 2
- 102000006822 Agouti Signaling Protein Human genes 0.000 description 2
- 108010072151 Agouti Signaling Protein Proteins 0.000 description 2
- 235000008078 Arctium minus Nutrition 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 2
- 240000000912 Macadamia tetraphylla Species 0.000 description 2
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 2
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229910052768 actinide Inorganic materials 0.000 description 2
- 150000001255 actinides Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- NBWRJAOOMGASJP-UHFFFAOYSA-N 2-(3,5-diphenyl-1h-tetrazol-1-ium-2-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1N1N(C=2C=CC=CC=2)N=C(C=2C=CC=CC=2)[NH2+]1 NBWRJAOOMGASJP-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 101710197637 Actin-3 Proteins 0.000 description 1
- 108090000104 Actin-related protein 3 Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 101000756636 Dictyostelium discoideum Major actin Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 229930183217 Genin Natural products 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000034874 Product colour issue Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 235000012830 plain croissants Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
시험 물질 | 최종 실험 농도(㎍/㎖) | 멜라닌 생성 억제율(%) |
악 틴 | 60 | 67.3 |
100 | 78.5 | |
140 | 80.3 | |
180 | 84.2 | |
악티게닌 | 60 | 66.8 |
100 | 79.6 | |
140 | 81.3 | |
180 | 84.3 | |
악틴 및 악티게닌 1:3 혼합물 | 60 | 80.2 |
100 | 85.7 | |
140 | 89.3 | |
180 | 90.2 | |
악틴 및 악티게닌 3:1 혼합물 | 60 | 66.2 |
100 | 69.3 | |
140 | 77.2 | |
180 | 80.3 |
악틴 | 악티게닌 | 악틴 및 악티게닌 3:1 혼합물 | 악틴 및 악티게닌 1:3 혼합물 | 멜라노사이트 자극호르몬 | 티로시나제 밴드 강도 | |
대조예1 | - | - | - | - | 0 | 123 |
대조예2 | - | - | - | - | 100 | 211 |
실시예1 | 100 | - | - | - | 100 | 155 |
실시예2 | - | 100 | - | - | 100 | 135 |
실시예3 | - | - | 100 | - | 100 | 145 |
실시예4 | - | - | - | 100 | 100 | 129 |
시험 물질 | 최종 실험 농도(㎍/㎖) | 세포생존율 (%) |
악 틴 | 20 | 102.1 |
60 | 101.3 | |
100 | 99.8 | |
140 | 98.7 | |
180 | 98.7 | |
악티게닌 | 20 | 101.2 |
60 | 101.0 | |
100 | 99.8 | |
140 | 97.6 | |
180 | 96.7 | |
악틴 및 악티게닌 1:3 혼합물 | 20 | 99.8 |
60 | 98.7 | |
100 | 94.8 | |
140 | 98.3 | |
180 | 96.8 | |
악틴 및 악티게닌 3:1 혼합 | 20 | 101.1 |
60 | 100.3 | |
100 | 99.8 | |
140 | 99.9 | |
180 | 97.7 |
세포 생존율 범위 | 독성판정 |
생존률 70% 이하 | 중독성 |
70% 초과 80% 이하 | 경독성 |
80% 초과 90% 이하 | 미독성 |
90% 초과 | 무독성 |
성분함량(중량%) | 대조예3 | 실시예5 | 실시예6 | 실시예7 | 비교예1 |
악틴 | - | 3.0 | - | 1.5 | - |
악티게닌 | - | - | 3.0 | 1.5 | - |
알부틴 | - | - | - | - | 3.0 |
글리세린 | 5.1 | 5.1 | 5.1 | 5.1 | 5.1 |
프로필렌글리콜 | 4.2 | 4.2 | 4.2 | 4.2 | 4.2 |
토코페릴아세테이트 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 |
유동파라핀 | 4.6 | 4.6 | 4.6 | 4.6 | 4.6 |
트리에탄올아민 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
스쿠알란 | 3.1 | 3.1 | 3.1 | 3.1 | 3.1 |
마카다미아너트오일 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
폴리솔베이트60 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 |
솔비탄세스퀴롤레이트 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 |
프로필파라벤 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 |
카르복실비닐폴리머 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
향 | 미량 | 미량 | 미량 | 미량 | 미량 |
방부제 | 미량 | 미량 | 미량 | 미량 | 미량 |
정제수 | 잔량 | 잔량 | 잔량 | 잔량 | 잔량 |
계 | 100 | 100 | 100 | 100 | 100 |
유효 | 약간 유효 | 무효 | 유효율(%) | |
대조예 3 | 3 | 7 | 10 | 15.0 |
실시예 5 | 15 | 3 | 2 | 90.0 |
실시예 6 | 16 | 2 | 2 | 90.0 |
실시예 7 | 18 | 1 | 1 | 95.0 |
비교예 1 | 12 | 3 | 5 | 75.0 |
기호 | 점수 | 평가기준 |
- | 0 | 무반응, 정상 피부 |
± | 0.5 | 희미한 또는 가벼운 홍반 |
+ | 1.0 | 경계가 뚜렷하나 약한 홍반, 부종 및 구진 |
++ | 2.0 | 뚜렷한 홍반, 구진 및 소수포 |
+++ | 3.0 | 심한 홍반 및 소포형성 |
++++ | 6.0 | 대수포 형성 |
시험 물질 | 24 시간 | 48 시간 | 평균 피부 반응도 (n=20) |
± + ++ | ± + ++ | ||
대조예 3 | 1 - - | 1 - - | 0.42 |
실시예 5 | 1 - - | 1 - - | 0.42 |
실시예 6 | 1 - - | 1 - - | 0.42 |
실시예 7 | 1 - - | 1 - - | 0.42 |
비교예 1 | 1 - - | 1 - - | 0.42 |
점수 | 평가 기준 |
0 | 변화 없음 |
1 | 극히 조금 변함 |
2 | 조금 변함 |
3 | 조금 심하게 변함 |
4 | 심하게 변함 |
5 | 극히 심하게 변함 |
45℃ | 4℃ | |
대조예 3 | 0 | 0 |
실시예 5 | 0 | 0 |
실시예 6 | 0 | 0 |
실시예 7 | 0 | 0 |
비교예 1 | 1 | 0 |
성분(중량%) | 제형예 1 | 제형예 2 | 제형예 3 |
악틴 | 1.0 | - | 2.0 |
악티게닌 | - | 1.0 | 2.0 |
1,3-부틸렌글리콜 | 5.2 | 5.2 | 5.2 |
올레일알코올 | 1.5 | 1.5 | 1.5 |
에탄올 | 3.2 | 3.2 | 3.2 |
폴리솔베이트 20 | 3.2 | 3.2 | 3.2 |
벤조페논-9 | 2.0 | 2.0 | 2.0 |
카르복실비닐폴리머 | 1.0 | 1.0 | 1.0 |
글리세린 | 3.5 | 3.5 | 3.5 |
향 | 미량 | 미량 | 미량 |
방부제 | 미량 | 미량 | 미량 |
정제수 | 잔량 | 잔량 | 잔량 |
계 | 100 | 100 | 100 |
성분(중량%) | 제형예 4 | 제형예 5 | 제형예 6 |
악틴 | 2.5 | - | 1 |
악티게닌 | - | 1.5 | 7 |
글리세린 | 5.1 | 5.1 | 5.1 |
프로필렌글리콜 | 4.2 | 4.2 | 4.2 |
토코페릴아세테이트 | 3.0 | 3.0 | 3.0 |
유동파라핀 | 4.6 | 4.6 | 4.6 |
트리에탄올아민 | 1.0 | 1.0 | 1.0 |
스쿠알란 | 3.1 | 3.1 | 3.1 |
마카다미아너트오일 | 2.5 | 2.5 | 2.5 |
폴리솔베이트60 | 1.6 | 1.6 | 1.6 |
솔비탄세스퀴롤레이트 | 1.6 | 1.6 | 1.6 |
프로필파라벤 | 0.6 | 0.6 | 0.6 |
카르복실비닐폴리머 | 1.5 | 1.5 | 1.5 |
향 | 미량 | 미량 | 미량 |
방부제 | 미량 | 미량 | 미량 |
정제수 | 잔량 | 잔량 | 잔량 |
계 | 100 | 100 | 100 |
성분(중량%) | 제형예 7 | 제형예 8 | 제형예 9 |
악틴 | 1 | - | 7 |
악티게닌 | - | 7 | 1 |
글리세린 | 4.0 | 4.0 | 4.0 |
바셀린 | 3.5 | 3.5 | 3.5 |
트리에탄올아민 | 2.1 | 2.1 | 2.1 |
유동파라핀 | 5.3 | 5.3 | 5.3 |
스쿠알란 | 3.0 | 3.0 | 3.0 |
밀납 | 2.6 | 2.6 | 2.6 |
토코페릴아세테이트 | 5.4 | 5.4 | 5.4 |
폴리솔베이트 60 | 3.2 | 3.2 | 3.2 |
카르복실비닐폴리머 | 1.0 | 1.0 | 1.0 |
솔비탄세스퀴올레이트 | 3.1 | 3.1 | 3.1 |
향 | 미량 | 미량 | 미량 |
방부제 | 미량 | 미량 | 미량 |
정제수 | 잔량 | 잔량 | 잔량 |
계 | 100 | 100 | 100 |
성분(중량%) | 제형예 1 | 제형예 11 | 제형예 12 |
악틴 | 3 | - | 3 |
악티게닌 | - | 5 | 5 |
글리세린 | 4.0 | 4.0 | 4.0 |
바셀린 | 3.5 | 3.5 | 3.5 |
트리에탄올아민 | 0.5 | 0.5 | 0.5 |
유동파라핀 | 24.0 | 24.0 | 24.0 |
스쿠알란 | 3.0 | 3.0 | 3.0 |
밀납 | 2.1 | 2.1 | 2.1 |
토코페릴아세테이트 | 0.1 | 0.1 | 0.1 |
폴리솔베이트 60 | 2.4 | 2.4 | 2.4 |
카르복실비닐폴리머 | 1.0 | 1.0 | 1.0 |
솔비탄세스퀴올레이트 | 2.3 | 2.3 | 2.3 |
향 | 미량 | 미량 | 미량 |
방부제 | 미량 | 미량 | 미량 |
정제수 | 잔량 | 잔량 | 잔량 |
계 | 100 | 100 | 100 |
성 분(중량%) | 제형예 13 | 제형예 14 | 제형예 15 |
악틴 | 2 | - | 3 |
악티게닌 | - | 5 | 3 |
에틸알코올 | 3.0 | 3.0 | 3.0 |
EDTA-2Na | 0.02 | 0.02 | 0.02 |
프로필렌 글리콜 | 5.1 | 5.1 | 5.1 |
글리셀린 | 4.5 | 4.5 | 4.5 |
카보폴 | 1.0 | 1.0 | 1.0 |
폴리옥사이드 | 0.1 | 0.1 | 0.1 |
방부제 | 미량 | 미량 | 미량 |
향 | 미량 | 미량 | 미량 |
정제수 | 잔량 | 잔량 | 잔량 |
계 | 100 | 100 | 100 |
Claims (5)
- 악틴(Arctiin), 악티게닌(Arctigenin) 또는 그의 혼합물을 유효성분으로 함유하는 피부미백용 화장료 조성물.
- 제 1항에 있어서, 상기 악틴(Arctiin), 악티게닌(Arctigenin)또는 그의 혼합물은 화장료의 총 중량에 대하여 0.00001 내지 40.0 중량%를 함유하는 피부미백용 화장료 조성물.
- 제 1 항에 있어서, 상기 악틴 및 악티게닌의 혼합물은 악틴 및 악티게닌이 100:1 내지 1:100의 중량비로 혼합되어 있는 것을 특징으로 하는 피부미백용 화장료 조성물.
- 제 1 항에 있어서, 상기 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이로 구성된 군으로부터 선택되는 제형을 갖는 것을 특징으로 하는 피부미백용 화장료 조성물.
- 제 1 항의 화장료 조성물을 인간의 피부에 도포하는 것을 특징으로 하는 화장방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070020603A KR100855457B1 (ko) | 2007-02-28 | 2007-02-28 | 악틴, 악티게닌 또는 그의 혼합물을 유효성분으로 함유하는피부미백용 화장료 조성물 |
US12/449,727 US20100104524A1 (en) | 2007-02-28 | 2008-02-25 | Cosmetic composition for skin whitening comprising arctiin, arctigenin or the mixture thereof as active |
EP08723115.5A EP2114362B1 (en) | 2007-02-28 | 2008-02-25 | Cosmetic composition for skin whitening comprising a mixture of arctiin and arctigenin |
JP2009551949A JP5675112B2 (ja) | 2007-02-28 | 2008-02-25 | アルクチン、アルクチゲニン又はその混合物を有効成分として含有する皮膚美白用化粧料組成物 |
CN2008800021710A CN101578092B (zh) | 2007-02-28 | 2008-02-25 | 用于皮肤增白的含有牛蒡子甙、牛蒡子甙元或其混合物作为活性成分的化妆品组合物 |
PCT/KR2008/001077 WO2008105605A1 (en) | 2007-02-28 | 2008-02-25 | Cosmetic composition for skin whitening comprising arctiin, arctigenin or the mixture thereof as active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070020603A KR100855457B1 (ko) | 2007-02-28 | 2007-02-28 | 악틴, 악티게닌 또는 그의 혼합물을 유효성분으로 함유하는피부미백용 화장료 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100855457B1 true KR100855457B1 (ko) | 2008-09-01 |
Family
ID=39721414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070020603A KR100855457B1 (ko) | 2007-02-28 | 2007-02-28 | 악틴, 악티게닌 또는 그의 혼합물을 유효성분으로 함유하는피부미백용 화장료 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20100104524A1 (ko) |
EP (1) | EP2114362B1 (ko) |
JP (1) | JP5675112B2 (ko) |
KR (1) | KR100855457B1 (ko) |
CN (1) | CN101578092B (ko) |
WO (1) | WO2008105605A1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100968716B1 (ko) | 2007-03-07 | 2010-07-08 | 주식회사 코리아나화장품 | 악티게닌 또는 악티게닌 유도체를 유효성분으로 함유하는피부노화 방지용 화장료 조성물 |
KR101583777B1 (ko) | 2014-07-18 | 2016-01-08 | 경희대학교 산학협력단 | 아크틴의 신규 용도 |
KR20160011398A (ko) * | 2014-07-22 | 2016-02-01 | 주식회사 코리아나화장품 | 리포좀에 포접하여 안정화시킨 악틴 또는 악티게닌을 함유하는 화장료 조성물 |
CN115487098A (zh) * | 2022-10-23 | 2022-12-20 | 周嘉奇 | 一种护肤乳液及其制备方法 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011120339A1 (zh) * | 2010-04-03 | 2011-10-06 | 鲁南制药集团股份有限公司 | 牛蒡苷元的微乳制剂 |
CN102451178A (zh) * | 2010-10-29 | 2012-05-16 | 中国科学院上海药物研究所 | 二氢呋喃-2-酮类化合物在制备抗糖尿病及糖脂代谢药物中的用途 |
US8614211B2 (en) | 2011-08-10 | 2013-12-24 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US9675538B2 (en) | 2012-03-30 | 2017-06-13 | Rohto Pharmaceutical Co., Ltd. | Anti-aging agent containing arctigenin derivative |
EP2842607B1 (en) * | 2013-09-02 | 2018-05-30 | Symrise AG | A skin and/or hair whitening mixture |
ITUB20150330A1 (it) * | 2015-02-05 | 2016-08-05 | Novamont Spa | Processo per il frazionamento di semi di piante oleaginose. |
KR102394636B1 (ko) * | 2015-06-30 | 2022-05-09 | (주)아모레퍼시픽 | 피부 미백용 조성물 및 피부 미백 효능 물질을 스크리닝하는 방법 |
WO2017138586A1 (ja) * | 2016-02-08 | 2017-08-17 | クラシエホールディングス株式会社 | インフラマソーム活性化抑制剤 |
CN105769964A (zh) * | 2016-03-30 | 2016-07-20 | 苏州勤浩药物研究开发有限公司 | 牛蒡子提取物抗皮肤光老化的用途 |
JP6902329B2 (ja) * | 2016-04-04 | 2021-07-14 | クラシエホールディングス株式会社 | 皮脂腺細胞の活性化の抑制剤 |
JP6389308B1 (ja) * | 2017-08-23 | 2018-09-12 | 一丸ファルコス株式会社 | 皮膚外用剤 |
FR3078891B1 (fr) * | 2018-03-16 | 2020-12-25 | Centre Nat Rech Scient | Utilisation d’un extrait d’ilex aquifolium pour le traitement des desordres de la pigmentation et pour le blanchiment de la peau |
CN111514132A (zh) * | 2019-02-01 | 2020-08-11 | 鲁南制药集团股份有限公司 | 一种对疖痈具有防治作用的组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020080660A (ko) * | 2001-04-17 | 2002-10-26 | 김종헌 | 연교 추출물을 포함하는 미백제 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2977648B2 (ja) * | 1991-07-19 | 1999-11-15 | 鐘紡株式会社 | 養毛化粧料 |
JP3862765B2 (ja) * | 1994-04-11 | 2006-12-27 | 株式会社ナリス化粧品 | メラニン生成抑制物質 |
JP2000119156A (ja) * | 1998-10-14 | 2000-04-25 | Kose Corp | 皮膚外用剤 |
CN1292284A (zh) * | 1999-07-03 | 2001-04-25 | 王淑贞 | 一种湿敷面膜及其制备方法 |
JP3658548B2 (ja) * | 2000-10-24 | 2005-06-08 | 丸善製薬株式会社 | 美白化粧料 |
KR100638056B1 (ko) * | 2000-12-15 | 2006-10-24 | 주식회사 코리아나화장품 | 연교추출물을 함유한 미백제 |
JP2003081748A (ja) * | 2001-09-12 | 2003-03-19 | Pola Chem Ind Inc | メラノサイトのデンドライトの伸長抑制剤及びそれを含有する化粧料 |
JP2003246722A (ja) * | 2002-02-25 | 2003-09-02 | Kanebo Ltd | 美白化粧料 |
DE10223486A1 (de) * | 2002-05-27 | 2003-12-11 | Beiersdorf Ag | Kosmetische und/oder dermatologische Zubereitung mit 2,3-Dibenzylbutyrolactonen |
DE10305965A1 (de) * | 2003-02-12 | 2004-08-26 | Beiersdorf Ag | Kosmetische und/oder dermatologische Zubereitung |
DE10357451A1 (de) * | 2003-12-03 | 2005-07-07 | Beiersdorf Ag | Wirkstoffkombinationen aus 2,3-Dibenzylbutyrolactonen und Licochalcon A oder einem wässrigen Extrakt aus Radix Glycyrrhizae inflatae, enthaltend Licochalcon A |
KR100599491B1 (ko) * | 2005-08-09 | 2006-07-12 | 주식회사 사이버메드 | 수술용 항법장치용 프로브 |
CN100435829C (zh) * | 2005-12-24 | 2008-11-26 | 蒋艳群 | 一种调节人体内分泌、美容祛斑的中草药组合物 |
CN100394911C (zh) * | 2006-01-25 | 2008-06-18 | 郁俊明 | 祛除色斑的中草药面膜 |
KR100825450B1 (ko) * | 2006-06-30 | 2008-04-28 | 주식회사 사임당화장품 | 연교추출물을 함유하는 피부 주름개선용 화장료 조성물 |
-
2007
- 2007-02-28 KR KR1020070020603A patent/KR100855457B1/ko active IP Right Grant
-
2008
- 2008-02-25 CN CN2008800021710A patent/CN101578092B/zh active Active
- 2008-02-25 WO PCT/KR2008/001077 patent/WO2008105605A1/en active Application Filing
- 2008-02-25 US US12/449,727 patent/US20100104524A1/en not_active Abandoned
- 2008-02-25 EP EP08723115.5A patent/EP2114362B1/en active Active
- 2008-02-25 JP JP2009551949A patent/JP5675112B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020080660A (ko) * | 2001-04-17 | 2002-10-26 | 김종헌 | 연교 추출물을 포함하는 미백제 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100968716B1 (ko) | 2007-03-07 | 2010-07-08 | 주식회사 코리아나화장품 | 악티게닌 또는 악티게닌 유도체를 유효성분으로 함유하는피부노화 방지용 화장료 조성물 |
KR101583777B1 (ko) | 2014-07-18 | 2016-01-08 | 경희대학교 산학협력단 | 아크틴의 신규 용도 |
KR20160011398A (ko) * | 2014-07-22 | 2016-02-01 | 주식회사 코리아나화장품 | 리포좀에 포접하여 안정화시킨 악틴 또는 악티게닌을 함유하는 화장료 조성물 |
KR101631924B1 (ko) * | 2014-07-22 | 2016-06-20 | 주식회사 코리아나화장품 | 리포좀에 포접하여 안정화시킨 악틴 또는 악티게닌을 함유하는 화장료 조성물 |
CN115487098A (zh) * | 2022-10-23 | 2022-12-20 | 周嘉奇 | 一种护肤乳液及其制备方法 |
CN115487098B (zh) * | 2022-10-23 | 2024-02-27 | 深圳市理然化妆品有限公司 | 一种护肤乳液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP5675112B2 (ja) | 2015-02-25 |
WO2008105605A1 (en) | 2008-09-04 |
EP2114362A4 (en) | 2013-12-18 |
JP2010520233A (ja) | 2010-06-10 |
US20100104524A1 (en) | 2010-04-29 |
EP2114362B1 (en) | 2018-07-18 |
CN101578092B (zh) | 2011-08-03 |
EP2114362A1 (en) | 2009-11-11 |
CN101578092A (zh) | 2009-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100855457B1 (ko) | 악틴, 악티게닌 또는 그의 혼합물을 유효성분으로 함유하는피부미백용 화장료 조성물 | |
KR101131574B1 (ko) | 피부 미백용 조성물 | |
KR101551243B1 (ko) | 말굽버섯 추출물을 포함하는 피부미백용 화장료 조성물 | |
KR20180090123A (ko) | 리퀴댐버릭 락톤을 포함하는 화장료 조성물 | |
KR20180045626A (ko) | 발레클로린을 포함하는 화장료 조성물 | |
KR101525090B1 (ko) | 피부미백용 화장료 조성물 | |
KR20180027213A (ko) | 살비아놀산 c를 포함하는 화장료 조성물 | |
KR100495454B1 (ko) | 피토라이트를 포함하는 미백 화장료 조성물 | |
KR101317433B1 (ko) | 지구자, 길경, 밀싹 및 세이지 추출물을 함유하는 미백 화장용 조성물 | |
KR101230752B1 (ko) | 히스피듈린 또는 그 유도체를 함유하는 화장료 조성물 | |
KR100681700B1 (ko) | 생큐노라이드 a 및 글루콘산을 유효성분으로 함유하는피부 미백용 화장료 조성물 | |
KR101551240B1 (ko) | 검은 생강 추출물을 포함하는 피부미백용 화장료 조성물 | |
KR100540854B1 (ko) | 피토라이트 및 락테이트를 포함하는 미백 화장료 조성물 | |
KR102160306B1 (ko) | 피부미백제 | |
KR20180061662A (ko) | 아네모시드 a3을 포함하는 화장료 조성물 | |
KR101786606B1 (ko) | 테트란드린을 함유하는 화장료 조성물 | |
KR20130089559A (ko) | 항노화 조성물 | |
KR101348881B1 (ko) | 6-메톡시나린제닌 또는 그 유도체를 함유하는 화장료 조성물 | |
KR20180061663A (ko) | 디하이드로에보디아민을 포함하는 화장료 조성물 | |
KR20040060157A (ko) | 트라넥사믹산을 포함하는 피부 미백용 화장료 조성물 | |
KR100519851B1 (ko) | 디아세틸볼딘을 유효 성분으로 포함하는 미백 화장료 조성물 | |
KR102215168B1 (ko) | 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 함유하는 피부 미백용 조성물 | |
KR20060116362A (ko) | 상지추출물 및 코엔자임 q-10을 함유하는 피부 미백용화장료 조성물 | |
KR20010027446A (ko) | 폴리에톡실레이티드 비타민 씨 유도체를 함유하는 피부 미백용 화장료 조성물 | |
KR20140029654A (ko) | 보스웰릭산을 함유하는 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130628 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140618 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150626 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160628 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170629 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180626 Year of fee payment: 11 |